Department of Internal Medicine, Konkuk University School of Medicine, Konkuk University Hospital, Seoul, South Korea 2
|
|
- Neil Eaton
- 6 years ago
- Views:
Transcription
1 Antiviral Therapy 9 1: (doi: 1.351/IMP117) Original article Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir Won Hyeok Choe 1,, Sun Pyo Hong 3, Byung Kook Kim 1, Soon Young Ko 1, Young Kul Jung, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun, Kyun-Hwan Kim,5, Seung Il Ji 3, Soo-Ok Kim 3, Chang Hong Lee 1, and So Young Kwon 1, * 1 Department of Internal Medicine, Konkuk University School of Medicine, Konkuk University Hospital, Seoul, South Korea Center for Cancer Research and Diagnostic Medicine, Institute of Biomedical Science and Technology, Konkuk University, Seoul, South Korea 3 Research and Development Center, GeneMatrix, Inc., Yongin, South Korea Department of Internal Medicine, Korea University College of Medicine, Guro Hospital, Seoul, South Korea 5 Department of Pharmacology, Konkuk University School of Medicine, Seoul, South Korea *Corresponding author: sykwonmd@kuh.ac.kr These authors made an equal contribution to this work Background: The efficacy of entecavir (ETV) monotherapy in treatment-experienced patients with chronic hepatitis B (CHB) is debatable. Methods: A total of hepatitis B e antigen (HBeAg)- positive CHB patients who had shown viral breakthrough or suboptimal response with lamivudine () and adefovir disoproxil (ADV) therapy were treated with 1. mg of ETV. Clinical and virological parameters were monitored every 3 months. Restriction fragment mass polymorphism assays were used to detect antiviral resistance. Results: During and ADV therapy, 11 patients had rtmv/i mutations, had rta11v/t or rtn3t, 7 had both and had no - or ADV-related mutations. After switching to ETV monotherapy, the median change in serum hepatitis B virus (HBV) DNA level was -.1 log 1. Virological response (HBV DNA<3 ) was achieved in 1 of 1 patients with pre-existing rt mutations, whereas it was achieved in all patients without pre-existing rt mutations regardless of the presence of rt11 or rt3 mutations. Changes in mutational patterns during ETV therapy showed that rt mutations persisted or re-emerged. Relative abundances of rtmv/i mutations in total viral populations gradually increased under ETV rescue, whereas those with rta11v/t and rtn3t mutations decreased. ETV resistance mutations (rtl1m+rtt1i/l[rtsg]+rtmv) were detected in five patients with pre-existing rt mutations. Conclusions: ETV monotherapy resulted in a limited virological response in patients who had previously failed and ADV rescue therapy. The limited efficacy might be associated with residual or reselected rtmv/i mutations leading to ETV resistance. Combination treatment including potent antiviral agents should be recommended for patients with pre-existing rtmv/i mutations. Introduction Hepatitis B virus (HBV) replication has a key role in the disease progression and development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients [1 3]; therefore, the major goal of anti-hbv therapy is the sustained suppression of HBV replication without the emergence of drug resistance mutations and the prevention of hepatic decompensation and HCC []. Lamivudine () was the first oral agent approved for the treatment of CHB patients and was initially successful in suppressing HBV DNA [5]; however, the wide use of monotherapy during the past 1 years has led to a progressive increase in the number of patients with resistance because of its poor resistance profile []. Adefovir dipivoxil (ADV) was the second oral anti-hbv agent approved for first-line therapy or rescue therapy for resistance; however, long-term treatment with ADV has led to the emergence of ADV resistance [7]. Moreover, a higher rate of ADV resistance has been reported in patients with pre-existing - resistant mutations compared with treatment- 9 International Medical Press (print) -5 (online) 95
2 WH Choe et al. naive patients, especially in those treated with ADV monotherapy []. Recently, there has been increasing evidence indicating that the addition of ADV to continued therapy is associated with a lower rate of emergence of ADV resistance [9,1], but does not result in significantly improved viral suppression [9]. Entecavir (ETV) is a recently approved oral agent for treatment-naive or treatment-experienced CHB patients. ETV has an excellent potency and a high genetic barrier to resistance in treatment-naive patients [11,1]. The high genetic barrier to resistance is attributable to the requirement for three amino acid substitution mutations for resistance to occur, including two of the mutations associated with resistance (MV/I and L1M) plus an additional ETV-associated mutation at codons rt19, rt1, rt or rt5 [13]. Despite the great efficacy of ETV in treatment-naive patients, there is controversy about the antiviral efficacy of ETV in treatment-experienced CHB patients [1 1]. The aim of this study was to evaluate the antiviral efficacy of ETV in patients who had failed to achieve viral response during and ADV rescue therapy. We also investigated the evolution of antiviral resistance mutations and the emergence of HBV mutations associated with ETV resistance during ETV monotherapy by using restriction fragment mass polymorphism (RFMP) assays. Methods Patients Between September and September 7, CHB patients who had viral breakthrough or a suboptimal response to and ADV rescue therapy were included. The patients were treated with ETV monotherapy at a daily dose of 1. mg for 1 months. There was no time gap when the drugs were switched. They were followed-up every 3 months during ETV monotherapy for clinical assessments of tolerability, physical examination and blood sampling to measure laboratory parameters and HBV status. Serum HBV DNA levels were assessed using the COBAS Amplicor PCR assay (Roche Molecular Systems, Branchburg, NJ, USA) with a lower limit of detection of 3 (.5 log 1 ). This study was approved by the Institutional Review Board of the Konkuk University Hospital (Seoul, South Korea). Definitions Virological response was defined as a decrease in serum HBV DNA to an undetectable level (<.5 log 1 ) by PCR assay [19]. Viral breakthrough was defined as a 1 log 1 increase in HBV DNA from nadir after an initial decrease in HBV DNA by > log 1 [19]. Suboptimal response was arbitrarily defined as HBV DNA> log 1 after months of antiviral therapy []. Detection of antiviral-resistant mutations Serial samples were collected from each patient at the time of initiation of each antiviral agent, once every 3 months during treatment and at the time of viral breakthrough, and they were stored frozen at - C. For surveillance of HBV antiviral resistance mutations, the serum samples taken at baseline and at the time of viral breakthrough or suboptimal response to the prior or ADV treatment were tested. After switch to ETV monotherapy, mutational analysis of HBV polymerase in each patient was performed using the individual serial samples at 3-month intervals. Analysis of the mutations associated with (rt1 and rt) or ADV (rt11 and rt3) were performed with a matrix-assisted laser desorption/ionization time of flight mass spectrometry (MS)-based genotyping assay, termed RFMP, as previously described [1 ]. The RFMP assay system had a low detection limit of.5 log 1 of HBV DNA in serum [1] and could detect antiviral resistance mutations that constituted as little as 1% of the total viral population [19,]. In addition, its feasible range for measuring relative abundance ratio of mutant versus wild-type virus was from 5% to 95% when the total viral load was log 1 [3]. The predominance of mutations was arbitrarily defined as a twofold or greater increase of antiviral resistance mutants than wild type in this study. RFMP analysis of mutations associated with ETV resistance was established with following primer pairs: 5 -GGATGCCTGGGCTTTCGCAAG-3 (nucleotides 1 33) and 5 -GGATGCACTCCCA TAGG-3 (nucleotides 37 ) for codon rt19, 5 -GGATGTCCTGGCTCAGTTT-3 (nucleotides 7) and 5 -GGATGACAAATGGCACT-3 (nucleotides 93) for codon rt1, 5 -GGATG TGTTTGGCTTTC-3 (nucleotides 71 73) and 5 -TTGGCCCCCAGGATG TACCACATGATC-3 (nucleotides 7 7) for codon rt, 5 -GGATGT GTTTGGCTTTCAGTTAT-3 (nucleotides 71 73) and 5 -TTGGCCCCCAGGATGTACC ACATGATC-3 (nucleotides 7 7) for codon rt, and 5 -GGATGTCCCTTAACTTC-3 (nucleotide 5 7) and 5 -GGATGAGCTTCCAATTACATATCC-3 (nucleotides 9) for codon rt5. The underlined sequence in each primer introduced new FokI sites into the PCR products. The presence of mutations was analysed by MS of the 9-mer, 1-mer, 7-mer, 11-mer and 1-mer fragments for rti19t, rtsg, rtt1s, rtmv and rtm5v, respectively, followed by comparison to expected mass patterns summarized in Additional file 1. The RFMP assay results were validated by 1% concordance with those 9 9 International Medical Press
3 Entecavir rescue therapy for antiviral-resistant HBV obtained by repetitive direct sequencing. Analytical sensitivities were estimated to be.5 log 1 and lower limits of detection for minority viral populations of RFMP in detecting the ETV-resistant strains was 1% and was similar to those obtained in - or ADV-resistance-related mutant strains [1,]. Statistical analyses Results are reported as median (range). HBV DNA levels were logarithmically transformed for analysis. Continuous variables were compared with the twotailed Student s t-test and categorical variables with the two-tailed χ test or Fisher s exact test. P-values <.5 were considered as statistically significant. Results Patient characteristics prior to ETV monotherapy Baseline characteristics of patients prior to ETV monotherapy are summarized in Table 1. A total of patients were included. All patients were hepatitis B e antigen (HBeAg)-positive and negative for hepatitis B e antibodies. None of the patients were coinfected with HIV or hepatitis C virus. The patients had compensated liver disease and seven of them had liver cirrhosis. All patients had been treated with (1 mg/day) as the first-line therapy for a median of 15 months. During monotherapy, they experienced viral breakthrough or a suboptimal response to, and 1 patients among them were confirmed to have rtmv/i mutations. After viral breakthrough or suboptimal response to, was switched to ADV (1 mg/day); 1 patients were treated with ADV monotherapy and 1 patients were treated by adding on ADV while continuing. During ADV rescue therapy, all patients experienced viral breakthrough or a suboptimal response. Of the 1 patients who experienced viral breakthrough during ADV therapy, were confirmed to have rta11v/t and/or rtn3t mutations. Of the 1 patients who were suboptimal responders to ADV, 3 were confirmed to have rta11v/t mutations. Antiviral responses to ETV monotherapy At the start of ETV rescue therapy, the median HBV DNA level was. log 1 (range 5.9.). The median decreases of HBV DNA level were -1. and -. log 1 at 3 and months of ETV therapy, respectively. At the end of the observation period (median 13.5 months), the median decrease of HBV DNA level was -.1 log 1. Virological response was achieved in 5 (3%) patients after a median duration of 9. months (range. 1.) of ETV treatment. In the remaining 17 patients, 13 patients were suboptimal responders to ETV and patients experienced viral breakthrough. All four Table 1. Patient characteristics Baseline variable Value, n= Mean age, years (range) 5 (1 59) Sex Male, n 1 Female, n Hepatitis B e antigen status Positive, n Negative, n Liver disease Chronic hepatitis B, n 15 Cirrhosis, n 7 monotherapy prior to ADV therapy Median duration of treatment, months (range) 15. (7. 3.) Response to treatment Viral breakthrough, n 1 Suboptimal response, n MV/I, n 1 Wild type, n a ADV therapy prior to ETV therapy Median duration of ADV treatment, months (range) 15. (. 9.) ADV monotherapy, n 1 ADV+ combination, n 1 Response to ADV treatment Viral breakthrough, n 1 Suboptimal, n 1 MV/I, n 1 A11V/T, n 7 b A11V/T+N3T, n Wild type, n a 3 a Wild type at codons rt19, rt1, rt11, rt1, rt, rt, rt3 and rt5. b One patient had mutations rta11t and rtmi. ADV, adefovir dipivoxil; ETV, entecavir;, lamivudine. patients without pre-existing rtmv/i mutations (regardless of the presence or absence of pre-existing rta11v/t or rtn3t mutations) achieved virological response to ETV rescue, whereas only 1 of 1 patients with pre-existing rtmv/i mutations achieved virological response. The mean reduction in HBV DNA was significantly lower in patients with pre-existing rtmv/i mutations compared with patients without rtmv/i mutations at ETV treatment months 3,, 9 and 1, respectively (Figure 1). Univariate analyses showed that virological response was only significantly associated with an absence of pre-existing rtmv/i mutations (P<.1) among clinical and virological parameters, such as age, sex, liver cirrhosis, pre- existing - or ADV-resistant mutations, HBV DNA or alanine aminotransferase (ALT) levels at the start of ETV therapy and treatment duration. At the start of ETV rescue therapy, the median ALT level was IU/l (range 3 ) and of patients had an ALT level above the upper limit of normal (ULN; IU/l). ALT normalization Antiviral Therapy
4 WH Choe et al. was achieved in 11 of (55%) patients during ETV monotherapy and HBeAg seroconversion occurred in one patient. Treatment outcomes of the patients during ETV therapy are summarized in Table. Mutational analysis during ETV treatment At the initiation of ETV rescue therapy, rtmv/i mutations were detected in 1 patients and A11V/T and/or N3T mutations were detected in patients. One patient had both -resistant and ADV-resistant mutations, and three patients had wild type at multiple sites of HBV mutations associated with antiviral resistance. During ETV rescue therapy, MV/I mutations re-emerged or persisted, and their relative abundances in total viral populations gradually increased in the 15 of 1 patients with pre-existing -resistant mutations (Table 3). In five of those patients, ETV- resistant mutations (rtl1m+rtt1l/i+rtmv in two patients and rtl1m+rtsg+rtmv in three patients) were detected at a median of 1 months of ETV therapy (range 9 1 months; Figure ), and of 5 patients with ETV resistance mutations experienced viral breakthrough (patients 5 and 13). Representative RFMP analyses of mutations associated with ETV resistance in patient 9 and patient 13 are shown in Figure 3. Mutations at codons rt19 or rt5 were not detected in any patients. Changes in mutational patterns demonstrated that the relative abundances of ADVresistant mutations in total viral populations decreased under ETV rescue; however, 3 of 9 patients (patients 15, 1 and 1) still had ADV-resistant mutations at the last follow-up period (Table 3). Discussion This study demonstrated that ETV monotherapy is not effective in patients who failed and ADV as a rescue treatment, especially in patients with pre-existing rtmv/i mutations. We observed that pre- existing MV/I mutations persisted or re-emerged during ETV rescue therapy in those patients. ETV exhibits potent activity against HBV and the occurrence of ETV resistance mutations is extremely low [5,], with a cumulative genotypic resistance rate of 1.% at 5 years in treatment-naive patients [7]. However, antiviral efficacy of ETV against -resistant HBV is still unsatisfactory [1 1]. Clinical studies showed that ETV resulted in a limited virological response and ETV-resistant mutations emerged more frequently in -experienced patients compared with treatment-naive patients [,13]. Antiviral activity of ETV against ADV-resistant HBV is another controversial issue. Theoretically, rescue therapy with ETV was suggested to be beneficial for ADVresistant patients because of the different resistance profiles between ETV and ADV [,], and in vitro studies demonstrated that ADV-resistant mutations were susceptible to ETV [9,3]. However, recent clinical reports have offered conflicting results regarding the efficacy of ETV in CHB patients with ADV resistance [17,1]. Recently, Reijnders et al. [1] reported that ETV monotherapy dosed at 1 mg resulted in a limited virological response in patients with a persistently high level of viral replication during ADV treatment. However, in their study, 75% of the - and ADV- Figure 1. Viral decreases according to the pre-existing lamivudine resistance mutation rtmv/i Decrease of HBV DNA, log ETV monotherapy Months P< Patients with pre-existing -r mutations (n=1) Patients without pre-existing -r mutations (n=) ETV, entecavir; HBV, hepatitis B virus;, lamivudine; -r, lamivudine resistance. Table. Treatment outcomes of entecavir rescue therapy Baseline variable Value Median HBV DNA at initiation of ETV, log 1 (range). (5.9.) Median duration of ETV, months (range) 13.5 (1. 1.) Median HBV DNA decrease at months, log 1 (range) -. (.1 -.) Median HBV DNA decrease at last follow-up, log 1 (range) -.1 (1. -.9) Virological response to ETV, n (%) 5 (3) HBeAg seroconversion or loss of HBeAg, n (%) 1 (5) ETV, entecavir; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus. 9 9 International Medical Press
5 Entecavir rescue therapy for antiviral-resistant HBV Table 3. Changes in HBV DNA levels and mutational patterns during ETV rescue therapy ADV ± ETV treatment at the start ETV treatment at months ETV treatment at last follow-up Patient treatment treatment HBV DNA, Relative abundance a HBV DNA, Relative abundance a Duration of HBV DNA, Antiviral resistance number (rt) (rt11) log 1 rt rt11 log 1 rt rt11 ETV treatment, log 1 mutations months 1 I A 7. I A I A rtmi, rtl1m I A.5 I<M A 5. V/I>M A 1. rtmi 3 V A.7 V/I>M A 5. V A 15 5 rtmv, rtl1m V A.9 M A. NA b NA b 1 UD UD 5 I A. I>M A.9 I A rtsg, rtmv, rtl1m V/I A.3 V/I=M A 5. V/I A rtmv/i, rtl1m 7 V/I A.5 V A. V A rtmv, rtl1m V A. V<M A. V A 1. rtmv, rtl1m 9 V/I A.7 V/I A.1 V/I A 15.3 rtt1i/l, rtmv, rtl1m 1 V A 7. V A.9 V A 1. rtmv, rtl1m 11 I A. I A.9 I A 15. rtsg, rtmv, rtl1m 1 I T/A I=M T=A. I A 15.5 rtmi 13 V/I T c 7. M T c.7 V A rtsg, rtmv, rtl1m 1 I V/T/A 7. M V/T>A.7 I<M T=A 1.9 rtmi 15 V T/A 7. M T>A 5.7 M T<A 1.1 rta11t 1 V/I V 7. M V.1 M V=A 1 3. rta11v 17 I V 5.9 M V 5. I A 15. rtt1i, rtmv/i, rtl1m 1 I T M T.1 I<M T=A 1.9 rtmi, rta11t 19 M T/A. M T=A. NA b NA b 1 UD UD M V c 7.1 M V c UD NA b NA b 1 UD UD 1 M A.7 M A 3. NA b NA b 15 UD UD M A 7. M A 3.3 NA b NA b 15 UD UD The ± symbol indicates with or without treatment. The > and < symbols indicate which type is predominant, mutant or wild type. The = symbol indicates that the proportions of mutant type and wild type in total viral population are similar. a Restriction fragment mass polymorphism assays showed wild type at the codons rt19, rt1, rt and rt5. b The relative abundances were not applicable (NA) because total viral loads were < log 1 in samples at months after entecavir (ETV) treatment. c Patient 13 had rta11t with rtn3t and patient had rta11v with rtn3t. There were no patients who had only rtn3t. ADV, adefovir dipivoxil; HBV, hepatitis B virus; UD, undetectable (<.5 log 1 );, lamivudine. Antiviral Therapy
6 WH Choe et al. Figure. Changes in HBV DNA and ALT levels during antiviral therapy in five patients who had entecavir resistance mutations A rtm I I>M I V/I V rtl1 L L L M<L M rta11 A A A A A rtn3 N N N N N rts S S S S G>S C HBV DNA, log rtm I I I V V rtl1 M M M M M rta11 A A A A A rtn3 N N N N N rtt1 T T T I=T T rts S S S S G HBV DNA, log 1 1 ADV ETV E ADV rtm I M M I V/I rtl1 L L L L M=L rta11 A V V A A rtn3 N N N N N rtt1 T T T T I=T ADV ETV ADV+ ALT, IU/ ULN ALT, IU/ ULN ETV B D rtm V/I V/I V/I V/I V V rtl1 M M M M M M rta11 A A A A A A rtn3 N N N N N rtt1 T T T T T I/L HBV DNA, log 1 ADV ADV+ ETV rtm V/I M M V V V rtl1 M<L L L M M M rta11 A T T A A A rtn3 N N T>N N N N rts S S S S G G HBV DNA, log 1 ADV ADV+LMV ETV HBV DNA ALT level 1 ALT IU/l ULN ALT IU/l ULN HBV DNA, log ALT, IU/ ULN (A) Patient 5. (B) Patient 9. (C) Patient 11. (D) Patient 13. (E) Patient 17. All patient numbers correspond to those in Table 3. Hepatitis B virus (HBV) mutations associated with antiviral resistance are shown above each graph. The solid bar above each graph represents the duration of antiviral therapy. The vertical dotted line represents the start of adefovir or entecavir treatment. The horizontal dotted lines represent the lower limit of detection of HBV DNA (.5 log 1 ). The upper limit of normal (ULN) for alanine aminotranferase (ALT) is IU/l. ADV, adefovir dipivoxil; ETV, entecavir;, lamivudine; rt, reverse transcriptase International Medical Press
7 Entecavir rescue therapy for antiviral-resistant HBV Figure 3. Representative mass spectra showing mutations that are associated with entecavir resistance A Patient 9 Relative peak intensity,1.,1.7,19.,193. rt1i/l Relative peak intensity 3,39.3 3,17.3 rtv,1,15,15,175,,5,5,75,3 Mass to charge ratio 3,5 3,3 3,35 3, 3,5 Mass to charge ratio B Patient 13 Relative peak intensity 3,75.1 3, ,39. rtg Relative peak intensity 3,17.5 rtv 3,5 3,1 3,15 3, 3,5 Mass to charge ratio 3,5 3,3 3,35 3, 3,5 Mass to charge ratio (A) Mutations rt1i/l (,19. Da/,1. Da and,1. Da/,193. Da) and rtv (3,17. Da/3,39. Da) detected in patient 9. (B) Mutations rtg (3,113. Da/3,75. Da) and rtv (3,17. Da/3,39. Da) detected in patient 13. experienced patients had previously developed resistance; therefore, it is difficult to suggest that prior experience of ADV therapy or ADV resistance mutations might have affected the limited overall efficacy of ETV in those patients. In this study, patients who experienced viral breakthrough or suboptimal response during and ADV as a rescue therapy were treated with ETV monotherapy sequentially. Of these patients, 1 (%) patients had previously developed resistance, 15 (%) had showed suboptimal responses to ETV and (9%) patients experienced viral breakthrough during a median observation of 13.5 months with ETV monotherapy. Also, ETV-resistant mutations were detected in 5 (3%) patients at a median of 1 months of ETV therapy, and it appeared earlier and more frequently than was reported in previous studies on treatmentnaive patients or refractory patients [11,1]. The limited efficacy of ETV might be related to preexisting -resistant mutations. Our data showed that only 1 of the 1 patients with pre-existing resistant mutations achieved virological response and the presence of pre-existing -resistant mutation significantly reduced the virological response. Mutational analyses also demonstrated that -resistant mutations re-emerged or persisted and their relative abundances in total viral populations gradually increased under ETV monotherapy in most patients with pre-existing -resistant mutations. In addition, ETV-resistant mutations occurred among these patients. These results also suggest that pre-existing - resistant mutations could continue to be selected by ETV therapy. If we compare the five patients who had ETV- resistant mutations in Figure, their HBV DNA levels decreased transiently under ETV therapy, only when a proportion of wild-type at codon rtm was present at the start of ETV therapy. Subsequently, the response to ETV was blunted and remained relatively flat when the transition to MV/I mutations predominance took place for several months; thus, allowing the selection of the additional ETV-resistant substitutions required to overcome drug suppression and resulting in a viral breakthrough. This trend of association of evolution of MV/I mutations with Antiviral Therapy
8 WH Choe et al. clinical response to ETV is consistent with a previous in vitro study [31] indicating that MV/I mutations exhibited a higher relative level of phenotypic resistance to ETV; therefore, ETV monotherapy does not seem to be a good choice as a rescue for treatment of patients with pre-existing -resistant mutations. By contrast, ETV still has some importance in treatment-experienced patients, especially in suboptimal responders to or ADV without antiviralresistant mutations. In this study, all four patients who had not experienced -resistant mutations achieved virological response regardless of the presence or absence of pre-existing ADV-resistant mutations. Changes in mutational patterns under ETV therapy also demonstrated that the relative abundances of ADV-resistant mutations were slowly decreased; however, ADV- resistant mutations still remained in three of nine patients at the last follow-up. Although N3T and A11V/T mutants are susceptible to ETV in vitro, the potential presence of cross-resistance or other compensatory mutations in HBV polymerase might contribute to the persistence of ADV-resistant mutants. Further investigations are needed to clarify the persistence of ADV-resistant mutation during ETV monotherapy. Approval of multiple nucleoside/nucleotide analogues to clinical practice and their sequential or combinational use increase the chance of selection of HBV variants with complex mutational patterns; thus, there is a need to simultaneously analyse several mutational hotspots associated with antiviral resistance and for optimal management of CHB. In this study, we introduced an advanced RFMP-based assay that exploited differential lengths of oligonucleotides (7 1-mer) depending upon each codon associated with ETV resistance, which would not necessitate repetitive PCR and MS analyses for multiple mutations. The RFMP method sensitively and reproducibly detected known point mutations of amino acids in the reverse transcriptase domains of HBV polymerase. Analytical sensitivity and a lower limit of detection for the minority mutant population as low as.5 log 1 and 1% of RFMP assays for ETV mutation should enable early detection of treatment failure, subsequent intervention and prevention of drug resistance as it develops [1,]. However, there is a possibility that mutations in other codons that were not covered by the RFMP assay might contribute to the individualized drug response to a certain extent during sequential treatment; therefore, clonal identification of HBV quasispecies during longitudinal sampling and subsequent in vitro susceptibility testing of potential variants with or without known primary mutations against antiviral agents should be supplemented to elucidate the viral evolution and acquisition of multiple antiviral drug resistance mutations. Our patients were treated with as the first-line anti-hbv treatment and ADV as a rescue therapy. Recent guidelines for treatment of CHB patients no longer recommend as a first-line agent or sequential monotherapy [3,33]. In many Asian countries with HBV endemic areas, including Korea, many patients have already been treated with and ADV sequential therapy because of a relatively low cost and the drug-by-drug approval process of anti- HBV agents. However, the effective rescue therapy for patients who have suffered from treatment failure with the sequential therapy is still controversial. This study clearly demonstrated that ETV is not an ideal option for the rescue therapy for those who failed sequential treatment with and ADV. Recent guidelines recommend tenofovir disoproxil fumarate (TDF)-based therapy with or without a combination of nucleoside/ nucleotide analogues as a rescue for the treatment of these patients [3,33]. We have reported that TDF and combination markedly suppressed HBV replication in ADV-resistant patients with pre-existing resistance [3]. Combination treatment that includes TDF could be a useful therapeutic option for patients with and/or ADV resistance In conclusion, ETV monotherapy showed a limited antiviral efficacy in CHB patients who had previously failed and ADV rescue therapy. The suboptimal response to ETV rescue therapy could predispose HBV to emergence of ETV resistance mutations. The limited efficacy of ETV in those patients might be primarily related to persistence or reselection of pre-existing -resistant mutations. Sequential monotherapy with an anti-hbv agent should be avoided to prevent emergence of multidrug resistance of HBV. Further investigations for efficacy of ETV combined with potent antiviral agents are needed to provide the therapeutic strategies for antiviral-resistant patients. Acknowledgements This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A). Disclosure statement The authors declare no competing interests. Additional file Additional file 1: A supplementary file of an interpretation table for mass to genotype conversion in the RFMP assay can be found at uploads/documents/15_kwon_additional_file.pdf 99 9 International Medical Press
9 Entecavir rescue therapy for antiviral-resistant HBV References 1. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology ; 13:7.. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA ; 95: Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 5; 97:5 7.. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther ; : Lok AS. The maze of treatments for hepatitis B. N Engl J Med 5; 35: Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 5; 5 Suppl 1: Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology ; 131: Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after weeks of adefovir dipivoxil monotherapy. Hepatology ; 3: Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 7; 5: Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 15 lamivudine-resistant hepatitis B patients. Gastroenterology 7; 133: Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 9 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 7; 133: Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology ; : Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother ; : Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 9 weeks. Hepatology ; : Suzuki F, Toyoda J, Katano Y, et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol ; 3: Su CW, Wu JC, Lee SD. Is entecavir ideal for the treatment of lamivudine-refractory chronic hepatitis B? Hepatology ; : Kamar N, Milioto O, Alric L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation ; : Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 9; 5: Lok AS, Zoulim F, Locarnini S, et al. Antiviral drugresistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 7; :5 5.. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat 7; 1 Suppl 1: Hong SP, Kim NK, Hwang SG, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol ; :37.. Kim HS, Han KH, Ahn SH, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 5; 1: Lee CH, Kim SO, Byun KS, et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology ; 13: Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut ; 55: Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med ; 35: Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med ; 35: Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 9; 9: Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther ; 9: Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rta11v/t mutants on hepatitis B treatment failure. J Hepatol ; : Qi X, Xiong S, Yang H, et al. susceptibility of adefovirassociated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 7; 1: Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 5; 1: Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol ; : Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 7; 5: Choe WH, Kwon SY, Kim BK, et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int ; :1. Accepted for publication 13 June 9 Antiviral Therapy
Chronic Hepatitis B - Antiviral Resistance in Korea -
Chronic Hepatitis B - Antiviral Resistance in Korea - Young-Suk Lim University of Ulsan College of Medicine Asan Medical Center Seoul, Korea HBV Genome partially double-stranded DNA genome about 3200 nucleotides
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationEntecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients
Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients D.J. Tenney 1, K.A. Pokorowski 1, R.E. Rose 1, C.J. Baldick 1, B.J. Eggers 1, J. Fang 1, M.J. Wichroski 1,
More informationAntiviral Therapy 2012; 17: (doi: /IMP1945)
Antiviral Therapy 2012; 17:387 394 (doi: 10.3851/IMP1945) Original article HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine
More informationDynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative Chronic Hepatitis B
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2007) 25: 183-188 CASE REPORT Dynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationLong-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients
ORIGINAL ARTICLE Korean J Intern Med 2015;30:32-41 Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients Hyo Jin Kim,
More informationHigh efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
The Korean Journal of Hepatology 2012;18:75-83 http://dx.doi.org/10.3350/kjhep.2012.18.1.75 pissn: 1738-222X eissn: 2093-8047 Original Article High efficacy of adefovir and entecavir combination therapy
More informationOriginal article Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy
Antiviral Therapy 0; :0 0 (doi: 0./IMP0) Original article Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy Florian van Bömmel *,
More informationOriginal article Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B
Antiviral Therapy 2011; 16:469 477 (doi: 10.3851/IMP1772) Original article Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B Young Eun Chon 1, Seung Up Kim
More informationIdentification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir
Title Identification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir Author(s) Wong, DKH; Fung, JYY; Lai, CL; Yuen, RMF Citation Hong Kong Medical
More informationJournal of Antimicrobial Chemotherapy Advance Access published April 25, 2013
Journal of Antimicrobial Chemotherapy Advance Access published April 25, 213 J Antimicrob Chemother doi:1.193/jac/dkt147 Virological response to entecavir reduces the risk of liver disease progression
More informationAntiviral Therapy 14:
Antiviral Therapy 14:679 685 Original article Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy Man-Fung Yuen 1 *,
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationChronic hepatitis B - New goals, new treatment. New England Journal Of Medicine, 2008, v. 359 n. 23, p
Title Chronic hepatitis B - New goals, new treatment Author(s) Lai, CL; Yuen, MF Citation New England Journal Of Medicine, 2008, v. 359 n. 23, p. 2488-2491 Issued Date 2008 URL http://hdl.handle.net/10722/59270
More informationThe role of entecavir in the treatment of chronic hepatitis B
REVIEW The role of entecavir in the treatment of chronic hepatitis B Evangelini Dimou Vasilios Papadimitropoulos Stephanos J Hadziyannis Department of Medicine and Liver Unit, Henry Dunant Hospital, Athens,
More informationJ.C. WANG, L.L. HE, Q. CHEN 1. Introduction. Abstract. BACKGROUND: Either combination. European Review for Medical and Pharmacological Sciences
European Review for Medical and Pharmacological Sciences Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation
More informationOptimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance
Liver International ISSN 1478-3223 REVIEW ARTICLE Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug Fabien Zoulim 1,2 and Stephen Locarnini 3 1 INSERM, U1052,
More informationClinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
pissn 2287-2728 eissn 2287-285X Original Article https://doi.org/10.3350/cmh.2017.0005 Clinical and Molecular Hepatology 2017;23:323-330 Clinical characteristics of patients with chronic hepatitis B who
More informationManagement of Antiviral Resistance in Chronic Hepatitis B
Gut and Liver, Vol. 11, No. 2, March 217, pp. 189-195 eview Management of Antiviral esistance in Chronic Hepatitis B Young-Suk Lim Department of Gastroenterology, Liver Center, Asan Medical Center, University
More informationDisclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only
Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping
More informationChronic infection with the hepatitis B virus (HBV)
Adding-on Versus Switching-to Adefovir Therapy in Lamivudine-Resistant HBeAg-Negative Chronic Hepatitis B Irene Rapti, 1 Evangelini Dimou, 1,2 Panayota Mitsoula, 2 and Stephanos J. Hadziyannis 1,2 We studied
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationA tale of two patients
15 th Annual Resistance and Antiviral Therapy Meeting Dr Sanjay Bhagani Royal Free Hospital, London Thursday 29 September 2011, Royal College of Physicians, London A tale of two patients Sanjay Bhagani
More informationLow Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients
GASTROENTEROLOGY 2007;133:1445 1451 Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients PIETRO LAMPERTICO,* MAURO VIGANÒ,* ELENA MANENTI,*
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationThe presence of hepatitis B e antigen (HBeAg) is
Assessment of Current Criteria for Primary Nonresponse in Chronic Hepatitis B Patients Receiving Entecavir Therapy Young-Joo Yang, 1 Ju Hyun Shim, 2 Kang Mo Kim, 2 Young-Suk Lim, 2 and Han Chu Lee 2 A
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationAnalysis of Reverse Transcriptase Gene Mutations in the Hepatitis B Virus at a University Hospital in Korea
Original Article Diagnostic Genetics Ann Lab Med 2014;34:230-234 http://dx.doi.org/10.3343/alm.2014.34.3.230 ISSN 2234-3806 eissn 2234-3814 Analysis of Reverse Transcriptase Gene Mutations in the Hepatitis
More informationOur better understanding of the natural
TREATMENT OF CHRONIC HEPATITIS B: MASTERING THE BASICS ON A COMPLEX TOPIC Ke-Qin Hu, MD* ABSTRACT The availability of newer antiviral agents, as well as comprehensive treatment recommendations, has equipped
More informationVirologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
The Korean Journal of Hepatology 2011;17:261-267 http://dx.doi.org/10.3350/kjhep.2011.17.4.261 Original Article Virologic response is not durable after adefovir discontinuation in lamivudine-resistant
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationTreatment of chronic hepatitis B: Evolution over two decades_
doi:10.1111/j.1440-1746.2010.06545.x REVIEW Treatment of chronic hepatitis B: Evolution over two decades_6545 138..143 Man-Fung Yuen and Ching-Lung Lai Department of Medicine, the University of Hong Kong,
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationEfficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 2017;23:230-238 Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationMutazioni di HBV in corso di trattamento; quale approccio razionale?
Mutazioni di HBV in corso di trattamento; quale approccio razionale? Prevenire Interpretare Trattare Marco Lagget UODU Gastroenterologia ed Epatologia AOU San Giovanni Battista di Torino Prevenire 1) Timing
More informationResponse-guided antiviral therapy in chronic hepatitis B: nucleot(s)ide analogues vs. pegylated interferon
Response-guided antiviral therapy in chronic hepatitis B: Sang Hoon Ahn, M.D., Ph.D. Department of Internal Medicine, Yonsei University College of Medicine, Institute of Gastroenterology, Liver Cirrhosis
More informationCOMPARISON OF HBV RIBONUCLEASE H DOMAIN IN NAÏVE AND DRUG RESISTANT PATIENTS
HBV RIBONUCLEASE H DOMAIN IN PATIENTS WITH DRUG RESISTANT COMPARISON OF HBV RIBONUCLEASE H DOMAIN IN NAÏVE AND DRUG RESISTANT PATIENTS Surachai Amornsawadwattana, Pattaratida Sa-Nguanmoo, Preeyaporn Vichaiwattana,
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationPartial virological response to entecavir in treatment-naïve patients with chronic hepatitis B
Partial virological response to entecavir in treatment-naïve patients with chronic hepatitis B Young Eun Chon Department of Medicine The Graduate School, Yonsei University Partial virological response
More informationChronic hepatitis B virus (HBV) infection is an important. New and Emerging Treatment of Chronic Hepatitis B
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:285 294 New and Emerging Treatment of Chronic Hepatitis B EMMET B. KEEFFE* and PATRICK MARCELLIN *Division of Gastroenterology and Hepatology, Stanford University
More informationIs there a need for combination treatment? Yes!
18.0.2012 C Hep Meeting Berlin Is there a need for combination treatment? Yes! Florian van Bömmel University Hospital Leipzig Hepatology Section Germany Most patients respond to monotherapy with entecavir
More informationViral hepatitis Prevention Board. Clinical aspects of hepatitis B
Viral hepatitis Prevention Board Clinical aspects of hepatitis B Natural History and serological markers acute and chronic hepatitis B Acute hepatitis B Immune response Immunological tolerance Resolution
More informationGish RG and AC Gadano. J Vir Hep
Treatment in Hepatitis B and C There are options! Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s Hepatitis B Virus Epidemiology and natural history 400
More informationTreatment for chronic hepatitis B (CHB) disease is
Antiviral Activity and Safety of LB80380 in Hepatitis B e Antigen Positive Chronic Hepatitis B Patients with Lamivudine-Resistant Disease Man-Fung Yuen, 1 * Kwang-Hyub Han, 2 * Soon-Ho Um, 3 Seung Kew
More informationHigh Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen Positive Chronic Hepatitis B
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1047 1050 BRIEF COMMUNICATIONS High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen Positive
More informationEntecavir plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients with Suboptimal Response to Lamivudine plus Adefovir : A Randomized Trial
AAC Accepts, published online ahead of print on 19 March 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.00338-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 1 2 3 4 5
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationDual Therapy for Chronic Hepatitis B Virus
Dual Therapy for Chronic Hepatitis B Virus Hussien Elsiesy, MD, and Douglas Dieterich, MD Corresponding author Douglas Dieterich, MD Division of Liver Diseases, Mount Sinai School of Medicine, One Gustave
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationLandmarks for Prevention and Treatment
HBeAg-positive chronic hepatitis B Why do I treat my patient with a nucleos(t)ide analogue? Dr. Nancy Leung BSc(Lon) MSc(Lon) MBBS(Lon) MD(Lon), FRCP(Lon) FRCP(Edin) FHKCP FHKAM Consultant Physician, Alice
More informationClinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B
pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 217;23:154-159 Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve
More informationManagement of hepatitis B virus
Journal of Antimicrobial Chemotherapy Advance Access published May 14, 2008 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkn188 Management of hepatitis B virus Nidhi A. Singh and Nancy Reau* Section
More informationChronic HBV Management in 2013
Chronic HBV Management in 2013 Mohammad Hossein Somi MD Professor of Gastroentrology and hepatology Liver and Gastrointestinal Disease Research Center Tabriz University of Medical Sciences 1 HBV in 2013
More informationCurrent treatment guidelines consider nucleos(-
Entecavir Treatment for Chronic Hepatitis B: Adaptation Is Not Needed for the Majority of Naïve Patients with a Partial Virological Response Roeland Zoutendijk, 1 Jurriën G. P. Reijnders, 1 Ashley Brown,
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationentecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has
More informationHBeAg-negative chronic hepatitis B. with a nucleos(t)ide analogue?
4 th PARIS HEPATITIS CONFERENCE HBeAg-negative chronic hepatitis B Why do I treat my chronic hepatitis B patients with a nucleos(t)ide analogue? George V. Papatheodoridis, MD 2nd Department of Internal
More informationAntiviral-resistant hepatitis B virus: can we prevent this monster from growing?
Journal of Viral Hepatitis, 2007, 14 (Suppl. 1), 29 36 REVIEW Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? F. Zoulim, 1,2,3 M. Buti 4 and A. S. Lok 5 1 INSERM, U871,
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationDrug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management
2013 02 28 26 1 nfect Dis nfo, Vol. 26, No. 1, February 28, 2013 1 [ ] 4 nucleoside and nucleotide analogs, NAs chronic hepatitis B, CHB CHB HBV NAs HBV NAs [ ] [ ] 512.62 [ ] A [ ] 1007-8134(2013)01-0001-09
More informationApproximately 400 million people worldwide have
Long-Term Monitoring Shows Hepatitis B Virus Resistance to Entecavir in Nucleoside-Naïve Patients Is Rare Through 5 Years of Therapy Daniel J. Tenney, Ronald E. Rose, Carl J. Baldick, Kevin A. Pokornowski,
More informationEffects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
Gut and Liver, Vol. 11, No. 6, November 2017, pp. 828-834 ORiginal Article Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated
More informationThe Goal of HBV Therapy. Key Points. The Twin Pillars of HBV Therapy
How to Follow Once You tart Hepatitis B Treatment And When To Worry About esistance American College of Gastroenterology October 16, 21 ra Jacobson, MD Vincent Astor Professor of Medicine Chief, Division
More informationHepatitis B virus infection (HBV) is global epidemic. Current Treatment Strategies for the Management of Chronic Hepatitis B CHRONIC HEPATITIS B
CHRONIC HEPATITIS B Current Treatment Strategies for the Management of Chronic Hepatitis B Case Study and Commentary, Robert J. Wong, MD, and Walid S. Ayoub, MD ABSTRACT Objective: To review current treatment
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationPegasys Hepatitis B. Pegasys (peginterferon alfa-2a) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.02 Subject: Pegasys Hepatitis B Page: 1 of 5 Last Review Date: September 18, 2015 Pegasys Hepatitis
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationOriginal Article HBV gene mutations in six multidrug-resistant chronic hepatitis B patients in China
Int J Clin Exp Pathol 2016;9(2):2134-2140 www.ijcep.com /ISSN:1936-2625/IJCEP0019592 Original Article HBV gene mutations in six multidrug-resistant chronic hepatitis B patients in China Li-Juan Fu 1,2,
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationFebruary 8, World Journal of Gastroenterology. Re: ESPS Manuscript No Dear Dr. Qi:
February 8, 2017 World Journal of Gastroenterology Re: ESPS Manuscript No. 32025 Dear Dr. Qi: My co-authors and I respectfully submit the accompanying revised manuscript, Early hepatitis B viral DNA clearance
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Baraclude 0.5 mg film-coated tablets Baraclude 1 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Baraclude
More informationFive nucleos(t)ide analogues (NUCs) lamivudine,
Virological Breakthrough and Resistance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogues in Clinical Practice Chanunta Hongthanakorn, Watcharasak Chotiyaputta, Kelly Oberhelman, Robert
More informationUpdate on HBV Treatment
Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationAUSTRALIAN PRODUCT INFORMATION - BARACLUDE (ENTECAVIR)
AUSTRALIAN PRODUCT INFORMATION - BARACLUDE (ENTECAVIR) 1 NAME OF THE MEDICINE BARACLUDE entecavir BARACLUDE entecavir 2 QUALITATIVE AND QUANTITATIVE COMPOSITION BARACLUDE film coated tablets contain 0.5
More informationDovepress. Therapeutics and Clinical Risk Management. Melissa K Osborn
Therapeutics and Clinical Risk Management open access to scientific and medical research Open Access Full Text Article r e v i e w Safety and efficacy of telbivudine for the treatment of chronic hepatitis
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationC hronic hepatitis B (CHB) virus infection affects more
161 HEPATITIS Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications MF Yuen, HJ Yuan, D KH Wong, J CH Yuen, WM Wong, A OO Chan, B CY Wong, KC Lai, CL Lai... See end of article
More informationMutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey
Mutants and HBV vaccination Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Geographic Distribution of Chronic HBV Infection 400 million people are carrier of HBV Leading cause of cirrhosis and HCC
More informationHepatitis B virus (HBV) is a major public health
Hepatocellular Carcinoma Risk in Chronic Hepatitis B Virus Infected Compensated Cirrhosis Patients With Low Viral Load Dong Hyun Sinn, 1 Junggyu Lee, 1 Juna Goo, 2 Kyunga Kim, 2 Geum-Youn Gwak, 1 Yong-Han
More informationGilead Sciences, Durham, NC, USA
Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF () for Treatment of Chronic Hepatitis B (CHB) In Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil: Final Week 168
More informationHepatitis B therapy FOCUS ON VIRAL HEPATITIS. Hellan Kwon and Anna S. Lok
FOCUS ON VIRAL HEPATITIS Hepatitis B therapy Hellan Kwon and Anna S. Lok Abstract The goal of hepatitis B treatment is to prevent cirrhosis, liver decompensation and hepatocellular carcinoma. In clinical
More informationLong-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease
Antiviral Therapy 12:1295 133 Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Man-Fung Yuen, Wai-Kay
More informationApproximately 400 million people worldwide have. Hepatitis B Virus DNA Levels at Week 4 of Lamivudine Treatment Predict the 5-Year Ideal Response
Hepatitis B Virus DNA Levels at Week 4 of Lamivudine Treatment Predict the 5-Year Ideal Response Man-Fung Yuen, Daniel Yee-Tak Fong, Danny Ka-Ho Wong, John Chi-Hang Yuen, James Fung, and Ching-Lung Lai
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationA randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B
Antiviral Therapy 11:977 983 A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B Man-Fung Yuen 1 *, John Kim 2, Chung Ryeol Kim 2, Vincent
More informationUltra-Deep Pyrosequencing Detects Conserved Genomic Sites and Quantifies Linkage of Drug-Resistant Amino Acid Changes in the Hepatitis B Virus Genome
Ultra-Deep Pyrosequencing Detects Conserved Genomic Sites and Quantifies Linkage of Drug-Resistant Amino Acid Changes in the Hepatitis B Virus Genome Francisco Rodriguez-Frías 1,2 *, David Tabernero 1,2,
More information